Vaddi Krishna's Insider Trades & SAST Disclosures
Vaddi Krishna's most recent trade in Prelude Therapeutics Inc was a trade of 675,000 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on March 25, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Vaddi Krishna.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 25 Mar 2025 | 675,000 | 1,999,296 | - | 0.7 | 467,438 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 20 Mar 2025 | 15,000 | 1,324,296 | - | 0.7 | 10,959 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 20 Mar 2025 | 5,416 | 1,309,296 | - | 0.7 | 3,950 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Mar 2025 | 29,999 | 1,294,774 | - | 0.8 | 22,631 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Mar 2025 | 9,106 | 1,303,880 | - | 0.7 | 6,829 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.72 per share. | 12 Mar 2025 | 50,000 | 1,264,775 | - | 0.7 | 35,820 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.71 per share. | 12 Mar 2025 | 47,500 | 1,214,775 | - | 0.7 | 33,744 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 496,000 | 496,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 1.21 per share. | 31 Dec 2024 | 5,000 | 142,553 | - | 1.2 | 6,044 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 30 Dec 2024 | 10,000 | 137,553 | - | 1.2 | 12,000 | Common Stock |
| Prelude Therapeutics Inc | Vaddi Krishna | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.93 per share. | 18 Dec 2024 | 100,000 | 1,167,275 | - | 0.9 | 93,210 | Common Stock |
| Prelude Therapeutics Inc | Vaddi Krishna | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 18 Dec 2024 | 6,888 | 127,553 | - | 0.9 | 6,116 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 425,000 | 425,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.01 per share. | 24 May 2023 | 1,000 | 1,066,375 | - | 5.0 | 5,011 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.31 per share. | 24 May 2023 | 900 | 1,067,275 | - | 5.3 | 4,779 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.63 per share. | 23 May 2023 | 11,856 | 1,065,375 | - | 5.6 | 66,749 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.13 per share. | 20 Dec 2022 | 19,188 | 120,665 | - | 5.1 | 98,446 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 327,900 | 327,900 | - | - | Employee Stock Option (right to buy) | |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 12.13 per share. | 13 Dec 2021 | 8,000 | 1,053,519 | - | 12.1 | 97,035 | Common Stock |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 285,800 | 285,800 | - | - | Employee Stock Option (Right to Buy) | |
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 101,477 | 101,477 | - | - | Common Stock | ||
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 101,477 | 0 | - | - | Series A Preferred Stock | ||
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 0 | - | - | Series A Preferred Stock | ||
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 0 | - | - | Series A Preferred Stock | ||
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 551,774 | - | - | Common Stock | ||
| Prelude Therapeutics Inc | Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 551,776 | - | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges